Oragenics INC 10-Q quarterly reports

Oragenics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, a net loss of $2.5 million for the quarter, and continued concerns about its ability to continue as a going concern.

Oragenics reports significant capital raise and progress on its lead neurological drug candidate ONP-002, while addressing ongoing financial challenges and regaining NYSE compliance.

Oragenics, Inc. reported reduced Q2 losses and secured $15.2 million in post-quarter financing, extending its cash runway through the first half of 2026, while advancing its lead drug candidate ONP-002 for concussion.

Oragenics, a development-stage company, announced its financial results for the first quarter of 2025, highlighting its focus on developing ONP-002 for mild traumatic brain injury.

Oragenics Inc. reported its third quarter 2024 results, highlighting a strategic shift towards the development of its ONP-002 drug for mild traumatic brain injury while managing financial constraints.

Oragenics, Inc. reported its financial results for the second quarter of 2024, highlighting a strategic shift towards developing its brain injury treatment, ONP-002, while managing financial constraints.

Oragenics, Inc. reported a net loss of $2.45 million for the first quarter of 2024, while shifting its focus to the development of ONP-002 for mild traumatic brain injury.